CN108096238A - Application of the mangiferin and the like in slimming medicine or food is prepared - Google Patents
Application of the mangiferin and the like in slimming medicine or food is prepared Download PDFInfo
- Publication number
- CN108096238A CN108096238A CN201711363842.3A CN201711363842A CN108096238A CN 108096238 A CN108096238 A CN 108096238A CN 201711363842 A CN201711363842 A CN 201711363842A CN 108096238 A CN108096238 A CN 108096238A
- Authority
- CN
- China
- Prior art keywords
- mangiferin
- mango
- extract
- group
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 title claims abstract description 198
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 229940043357 mangiferin Drugs 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 235000014826 Mangifera indica Nutrition 0.000 claims abstract description 52
- 235000004936 Bromus mango Nutrition 0.000 claims abstract description 51
- 235000009184 Spondias indica Nutrition 0.000 claims abstract description 51
- 241001093152 Mangifera Species 0.000 claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 37
- 210000002966 serum Anatomy 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 102000016267 Leptin Human genes 0.000 claims abstract description 13
- 108010092277 Leptin Proteins 0.000 claims abstract description 13
- 229930182478 glucoside Natural products 0.000 claims abstract description 13
- 150000008131 glucosides Chemical class 0.000 claims abstract description 13
- 229940039781 leptin Drugs 0.000 claims abstract description 13
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 13
- 235000019789 appetite Nutrition 0.000 claims abstract description 11
- 230000036528 appetite Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 3
- -1 methoxyl group Chemical group 0.000 claims description 27
- 229920003266 Leaf® Polymers 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 230000009471 action Effects 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 230000003579 anti-obesity Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 229930003944 flavone Natural products 0.000 claims description 5
- 150000002213 flavones Chemical class 0.000 claims description 5
- 235000011949 flavones Nutrition 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 235000009200 high fat diet Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 description 25
- 238000003304 gavage Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 10
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 7
- 229960001243 orlistat Drugs 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000000636 white adipocyte Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 240000007228 Mangifera indica Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 239000002269 analeptic agent Substances 0.000 description 5
- 210000001593 brown adipocyte Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 101000883510 Bos taurus Chitinase-3-like protein 1 Proteins 0.000 description 2
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 2
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 101000993459 Mus musculus Metal transporter CNNM1 Proteins 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 102100036307 Protein HEXIM1 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 0 *C([C@]([C@]([C@@]1O)O)O[C@@](C(C2O)C(*)=CC(Oc(c3c4)cc(O*)c4O*)=C2C3O)[C@@]1O)O Chemical compound *C([C@]([C@]([C@@]1O)O)O[C@@](C(C2O)C(*)=CC(Oc(c3c4)cc(O*)c4O*)=C2C3O)[C@@]1O)O 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 1
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 241000484025 Cuniculus Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101001063890 Mus musculus Leptin Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 101150075901 htr2 gene Proteins 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of mangiferin (English names：) and the like or application of the mango leaf extract in slimming medicine or food is prepared mangiferin, it is characterized in that mangiferin and the like total content is 60 90% in the mango leaf extract, the mangiferin analog is a kind of monomeric compound or the mixture of arbitrary multiple compounds；Mangiferin containing therapeutically effective amount and the like or the pharmaceutical composition of mango glucoside extract and pharmaceutical acceptable carrier.Mechanism of action plays the effect of weight-reducing for TC and LDL C in the expression of Leptin in inhibition mice serum and then the appetite of influence mouse and reduction serum.
Description
Technical field：
The invention belongs to drugs and field of food.Specifically, the present invention relates to a kind of new application of drug, by compound
Either the trim of the plant extracts rich in mangiferin or mangiferin is used for weight reducing treatments or prevention to mangiferin.
Background technology：
With the development of modern society, the improvement of people's living standards, cardiovascular and cerebrovascular disease is the elderly's common disease, no
Only there is very high disability rate, and the life of patient can be threatened if being not treated in time.According to statistics, the whole world is every year because of the heart
The number of cranial vascular disease and death is up to 15,000,000 people, and the case fatality rate in various diseases occupy the first, and obesity is to cause
Diabetes, the major reason of cardiovascular and cerebrovascular disease, therefore one of fat hot spot for having become everybody concern.
The reason for for causing obesity, is exactly generally speaking that the intake of energy is more than the digestion of people's energy, makes excessive energy
Amount is stored in the situation of fat in human body.
At present there are three types of the fat mechanism for the treatment of, it is respectively：
Lipid is adjusted to absorb：90% triglycerides (TG) is included in fat, triglycerides is in pancreatic lipase
Monoglyceride (MG) and aliphatic acid (FA) are hydrolyzed under the action of (pancreatic lipase), then with bile acid (bile
Acids), lysophosphatidic acid (LPA) and cholesterol (Cholesterol) be collectively formed mixed micelle by enterocyte absorb and again
It synthesizes triglycerides to be stored in white adipocyte (WAT), constantly accumulation ultimately results in fat generation.Ao Lisi conducts
Pancreatic lipase inhibitors will not be broken down into monose and fat by inhibiting the activity of pancreatic lipase and then the triglyceride made in food
Acid, but be expelled directly out external.
Energy expenditure：Preadipocyte In Vitro is by Proliferation, Differentiation into white adipocyte (WAT) and brown fat cell
(BAT), the multiplication of white adipocyte increases and then causes fat metabolic disturbance, and free fatty acids in plasma is horizontal to be risen, into
And fat is synthesized again, excessive Fat Accumulation causes fat generation.Active ingredient inhibits the Proliferation, Differentiation of Preadipocyte,
PPARY and C/EBP α so during Proliferation, Differentiation are reduced, and then the multiplication that can inhibit white adipocyte is loose,
The synthesis of fat would not be caused to reach fat-reducing effect；Or by promoting to generate BAT, BAT is made to work as with light brown adipocyte
In UCP1 (uncoupling proteins 1) rise, UCP1 is horizontal to be risen and then heat consumption of energy and then fat-reducing effect.
Appetite associated hormone is adjusted：By activating the polypeptide of apocleisis polypeptide and appetite-suppressing in hypothalamus, god can be inhibited
Through p277 (NPY), melanin-concentrating hormone (MCH), agouti chromoprotein GAP-associated protein GAP (AgRP) rises satiety and reduces food
Object intake reaches fat-reducing effect, activates the hormone Cocaine-and amphetamine-regulated transcript (CART) of apocleisis, and preceding Melanocortins are former
(POMC), dopamine (DA), goes plus adrenaline (NE), serotonin (5-HT) z reduce food intake and reach fat-reducing effect；
Or by the way that CCK in intestines (cholecystokinin), GLP-1 (pancreas hyperglycaemia sample peptide 1), PYY (polypeptide YY) is promoted to generate pancreas islet
Insulin action controls appetite in hypothalamus；Or inhibit the generation of Ghrelin in stomach (hungry element) to control appetite in addition.This
Outside, can also by hormone or the indirect modulation of appetite of growth factor, such as leptin be exactly one can be by influencing appetite
And then adjust food intake dose and then treat a fat technology, under normal circumstances, leptin is to need energy in animal body
When body is made to generate hunger, body be made to generate satiety, but under pathologic condition, leptin water when energy is not required in animal body
It is flat to be positively correlated with weight.
Other mechanism：Fatty acid synthetase (FAS) is a key enzyme during Adipogenesis, and the activity for inhibiting it can
So that Fatty synthesis is disorderly, and then plays antiobesity action, C75 is exactly the compound of an inhibition FAS.
The fat drug for the treatment of at present：Fenfluramin and Locaserin is that release by promoting 5-HT and reduction are nibbled
The food intake dose of tooth class animal is lost weight, and the former because it is toxic for the formation of heart valve and by market, Hou Zheshi
5-HT2c receptor stimulating agents are not acted on for 5-HT2A and 5-HT2B receptors；Rimonabant is that a selectivity is reversible
CB-1 receptor stimulating agents, CB-1 receptors are during preadipocyte differentiation and process that TG is synthesized with fatty acid biological
In can increase, it is fat that it was used for treatment in 2006, however it has the side effects such as introgression also by market；
Sibutramine is the 5-HT-NE reuptaking inhibitors of FDA approvals in 1997, it is reached by influencing hunger and satiety
To fat-reducing effect, but cause it in 2010 by market since it can increase cardiovascular complication possibility；
Orlistat is the irreversible pancreatic lipase inhibitors of first selectivity by FDA approvals in 1999, with others weight-reducing medicine phases
Compare, its side effect is relatively minimal；GLP-1 is a kind of hormone of enteral release, it can promote insulin and suppression
Glucagon processed and then the glucose level in liver is caused to reduce, and GLP-1 receptor stimulating agents can be by reducing energy
Intake reach fat-reducing effect, Exenatide and Liraglutide are approval in FDA and 2005 year respectively for treating fertilizer
Fat CLP-1 receptor stimulating agents[21]With the CLP-1 receptor stimulating agents for being used to treat diabetes of approval in 2014；
Phentermin/Topiramate is the slimming drugs for the drug combination for being proved sympathomimetic and anti-epileptic in 2010.
The application of mangiferin：Popular name (the Classification system of mango Shi Mango (Chinese Plants will)：Mangifera indica
L.), mango is a kind of evergreen megaphanerophyte of Anacardiaceae of original India, leaf keratin, alternate；Spend small, polygamy, yellow or faint yellow,
Into the panicle of basidixed.Mango is as a kind of common tropical fruit (tree), rich in there are many nutritional ingredient, and mangiferin
(mangiferin) as a kind of ingredient of the content inside mango compared with horn of plenty, it is easy to get and measures big.
Currently for there are many researchs of this ingredient of mangiferin in mango, mangiferin has good antioxidation activity,
Hydroxyl radical free radical can be removed, can inhibit anti-lipid peroxidation and the damage of DNA in testing in vitro；With antibacterial,
Anti-inflammatory, anticancer and having in terms of cardiovascular and cerebrovascular disease has certain effect；A part of researcher has found that mangiferin can press down
The expression of iNOS and TNF-α genes processed；There is researcher to study and find that mangiferin has 3T3-L1 cells inhibition well to make
With；There can be agonism to PPAR α receptors and regulate and control MAPK signal paths by being combined with heat shock protein 5；
It can promote the Proliferation, Differentiation of epidermal cell and the kidney and cardiac effect of mouse can be protected.Although mangiferin has such
Various bioactivity, but its effect in terms of biological fat-reducing has not been reported, the present invention is screened by Preliminary activation and found
Compound weight-reducing performance, and mechanism of action mechanism is still indefinite.The present invention is by giving obesity mice C57BL/6J to take orally not
With the mangiferin of concentration, and then explore the mechanism mechanism of antiobesity action in mangiferin body.
The content of the invention
Present invention aims at provide a kind of extract by being obtained in mango leaf, its preparation method and it making
Application in standby slimming medicine.
Following technical solution is to realize the above-mentioned purpose of the present invention.
Application of the mangiferin and the like in slimming medicine or food is prepared, it is characterised in that the mango leaf extraction
Mangiferin and the like total content is 60-90% in object, and the mangiferin analog is a kind of monomeric compound or arbitrary more
The mixture of kind compound, the mangiferin analog structural formula general formula are as follows：
Wherein, R1、R7For formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl, methylol, ethoxy, carboxyphenyl and various sugar
Compound；R8、R10For the compound of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl and various sugar；R11For hydrogen, hydroxyl, first
Oxygroup, ethyoxyl, methylol, ethoxy, carboxymethyl, carboxyethyl.
Application of the mangiferin and the like in slimming medicine or food is prepared, the mangiferin are carried by following methods
Take acquisition：It is dried after 40 kilograms of mango leaf harvestings, breaks into coarse powder, 60% ethanol water, dip time 6h, solid-liquid ratio 1:20,
Then purified with carrying out initial gross separation to mango flavones crude extract on last stage using macroreticular resin, Mobile state of going forward side by side absorption,
Elution；After the extract obtained sodium bicarbonate solution dissolving with pH=8 of previous step, the acetic acid for adding in certain 75% precipitates to obtain awns
Mangiferin crude product methanol at 40 DEG C is dissolved by heating, initial dissolution body is concentrated into after being completely dissolved by berry extract crude product 100g
First subcrystalline mangiferin in 4 DEG C of crystallisation by cooling, is repeated above step and crystallized again by long-pending 15%, finally obtain 95% with
On mangiferin.
Application of the mango leaf extract in slimming medicine or food is prepared, in the mango leaf extract mangiferin and its
Analog total content is 60-90%, and the mango leaf extract is extracted by following methods and obtained：After 40 kilograms of mango leaf harvestings
It dries, breaks into coarse powder, 60% ethanol water, dip time 6h, solid-liquid ratio 1:20, then use using macroreticular resin to upper single order
The mango flavones crude extract of section carries out initial gross separation purifying, Mobile state of going forward side by side absorption, elution；Extract obtained by previous step is used
After the sodium bicarbonate solution dissolving of pH=8, the acetic acid for adding in certain 75% precipitates to obtain mango extract crude product 100g.It is wherein described
Mango leaf extract be using following general structural formula compound represented flavonoids and flavonoid glycoside compounds as main component,
In formula, R1、R7For formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl, methylol, ethoxy, carboxyphenyl and various sugar
Compound；R8、R10For the compound of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl and various sugar；R11For hydrogen, hydroxyl, first
Oxygroup, ethyoxyl, methylol, ethoxy, carboxymethyl, carboxyethyl.
Mangiferin and the like or mango glucoside extract are preparing the medicine for the treatment of obesity caused by high fat diet
Application in object.
According to the application, mangiferin and the like action pathway to inhibit the expression of Leptin in serum, and then
The appetite of organism is influenced, TC and LDL-C in serum is reduced, so as to play antiobesity action.
Pharmaceutical composition, the mangiferin containing therapeutically effective amount and the like or mango glucoside extract and pharmaceutically acceptable load
Body.
According to the pharmaceutical composition, wherein described mangiferin and the like is needed because of dissolving and pharmacodynamics toxicology
It asks, further difference or any or several compounds mixing add in sulfonyls, phosphate radical, sodium salt, sylvite.
The present invention prepares related drugs and health care products or food supplement product with antiobesity action by mango leaf, and mango leaf is one
The raw material that is easy to get is planted, extract has antiobesity action.
Mango leaf extract is carried out anti-obesity activity screening by the present invention, it is found that there is the plant stem-leaf certain weight-reducing to live
Property, and antiobesity action Exploration on mechanism is carried out, mango leaf is developed as Related product, can increase the added value of fruit industry.
Drug of the present invention can be used for obesity.Compared with existing marketed drugs, drug of the present invention has curative effect highly significant, clothes
Dose is low, the advantages that facilitating patient.
Description of the drawings：
Fig. 1：The final weight of experiment mice and changes of weight percentage, n >=7 in figure,
Fig. 2：Each group mouse food-intake, wherein A are prevention groups, and B is treatment group
Fig. 3：The four items of blood lipid tests indicatrix of mice serum, wherein * represent P<0.05, * * represents P<0.01,±SE
Fig. 4：To fatty acid synthetase activity, n >=7, * represent P for leptin content and mangiferin in mice serum<
0.05, * * represents P<0.01,
Fig. 5：Mouse adipose and hepatic tissue section figure (20 times) wherein A are adipose tissue sections, and B is hepatic tissue section,
It is using Yihong-hematoxylin dyeing.
Specific embodiment：
Below in conjunction with the accompanying drawings, the essentiality content further illustrated the present invention with the embodiment of the present invention, but not with
This limits the present invention.
Embodiment 1
It is prepared by a kind of mango leaf extract：It is dried after the harvesting of 40 kilograms of mango leafs, breaks into coarse powder, 60% ethanol water,
Dip time 6h, solid-liquid ratio 1:20, then mango flavones crude extract on last stage is tentatively divided with using macroreticular resin
From purifying, Mobile state of going forward side by side absorption, elution；After the extract obtained sodium bicarbonate solution dissolving with pH=8 of previous step, add in
Certain 75% acetic acid precipitates to obtain mango extract crude product 100g.
Mangiferin purifies:Mango glucoside extract (crude product) 80g methanol obtained above is dissolved by heating at 40 DEG C first,
Percent the 15% of initial volume are concentrated into after being completely dissolved, in 4 DEG C of crystallisation by cooling；More than first subcrystalline mangiferin repetition
Step crystallizes again, finally obtains 95% and obtains mangiferin 15g.
Mangiferin method for preparing analogue：
Wherein X=Cl, Br, I work as R=CH3When, product 6mg；R=CH2CH3When, product 3mg.
R=CH3, product 20mg.
2mg products are obtained by the reaction in this.
Product 20mg is obtained by the reaction in this.
Embodiment 2：
Mangiferin weight-reducing pharmacodynamic experiment：
Experiment material：
Animal：C57BL/6J mouse 96, male mouse.
Test medicine：Mangiferin positive control medicine：Orlistat
Kit：Mouse Leptin kit (biology Co., Ltd of connection section, Hangzhou, China)；Mouse adipose acid enzyme with
And mouse adipose acid enzyme kit (the enzyme-linked bio tech ltd in Shanghai, Shanghai, China)；Hold agent preparation and weigh 25g
CMC-Na adds the heating of 5000ml distilled water electric furnace to make dissolving, cools down.
Grouping and administration are as follows：
Gavage principle：Every liquor capacity gavage for being no more than 0.6mL of mouse, daily gavage is once.
Grouping and dosage are as follows
Prevention group：
(1) 1 is normally organized：Normal diet, while gavage 0.5%CMC-Na solution 1 time to experiment terminates daily.
(2) mangiferin high dose group (200mg/kg/D)：High lipid food to experiment terminates, gavage mangiferin high dose solution
Terminate to experiment.
(3) mangiferin low dose group (50mg/kg/D)：High lipid food to experiment terminates, gavage mangiferin low dosage solution
Terminate to experiment.
Modeling animal is divided into following groups
(1) 2 are normally organized：Normal diet, while gavage 0.5%CMC-Na solution 1 time daily, gavage 21 days.
(2) model control group：High lipid food to experiment terminates, while gavage 0.5%CMC-Na solution 1 time daily, gavage
21 days.
(3) positive controls (55mg/kg/D)：High lipid food to experiment terminates, gavage Orlistat solution 21 days.
(4) treatment group's mangiferin high dose group (200mg/kg/D)：High lipid food to experiment terminates, the high agent of gavage mangiferin
Measure solution 21 days.
(5) treatment group's mangiferin low dose group (50mg/kg/D)：High lipid food to experiment terminates, low dose of gavage mangiferin
Measure solution 21 days.
Experiment content：
Mouse obese model modeling：
C57BL/6J of the weight in 14-16g under the normal condition of laboratory is adapted to after a week, separates 20 works at random
Normally to organize 1 and normal group 2,4 groups of mangiferin high dose, low dosage, every group of 7-9 only, corresponds to the molten medicine solvent of gavage, mango respectively
Glycosides high dose, low dosage solution terminate until experiment, record weight and food ration daily, are fed to commonly raise in laboratory conditions
Material.Remaining mouse is fed to the high lipid food (formula of same recipe：Protein 20%, carbohydrate 20%, lard 60%) into
The fat modeling of row, modeling 30 days claim weight, a food ration in during which every 6 days.
Mangiferin weight-reducing effect experiment is investigated：
This experiment is divided into prevention group and treatment group
Prevention group：Mouse after adapting to one week is randomly divided into normal group 1, mangiferin high dose, 3 groups of low dosage, often
Group 8, corresponds to the molten medicine solvent of gavage, mangiferin high dose, low dosage solution to experiment terminates respectively.
Treatment group：Normal group 2, normal diet, while gavage 0.5%CMC-Na solution 1 time daily, gavage 21 days；It will be through
It is excessive to cross the rat rejecting weight differences of fat modeling, is randomly divided into the high agent of model control group, positive controls, mangiferin
Amount, 4 groups of low dosage, every group of 7-9 only, correspond to the molten medicine solvent of gavage, positive drug, mangiferin high dose, low dosage solution respectively
21 days.The molten medicine solvent of normal group group gavage.Period modeling each group continues to be fed to high lipid food.Normal group is still fed to commonly raise
Material.It weighs daily, is administered the 22nd day, all mouse are plucked into eyeball and take blood, by serum sample preparation method and kit requirement system
Standby serum sample,
The preparation of serum sample：
After each group rat oral gavage 21 days, fasting 12h, can't help water after last time gavage.It 22nd day, plucks eyeball and takes blood,
When standing 0.5-1 is small, 15min is centrifuged with high speed freezing centrifuge 3000r/min, takes supernatant that serum sample is made, is placed in -20
DEG C refrigerator freezing preserves, and is measured for serum biochemistry.
As a result with analysis：
Table 1：Fat, liver and the weight of lung and Lee's Index and BMI indexes
Note：N >=7, ★ represent P<0.05, ★ ★ represents P<0.01,Lee's Index=weight (g) ^ (1/
3)/body length (cm), square (m of BMI=weight (KG)/height2)
As can be seen that the Lee indexes and BMI indexes of prevention group mangiferin low dosage have significantly compared with model group
Difference, this shows that mangiferin long-term use can pre- preventing obesity.
Each group complicated variant weight：Normal control group .1 (24.98g), model group (32.05g), the high dose group of prevention
(31.04g), the low dose group (28.09g) of prevention
Changes of weight percentage situation：Normal control group .2 (- 0.4), model group (- 2.1), Orlistat groups (- 7.3),
Mangiferin low dose group (- 3.0), mangiferin high dose group (- 2.1)
It can be seen that Orlistat (55mg/kg/D) and treatment group's mangiferin high dose (200mg/kg/D), mangiferin are low
Dosage (50mg/kg/D) has significant antiobesity action.
It will be seen from figure 1 that prevention group mangiferin high dose (200mg/kg/D), mangiferin low dosage (50 mg/kg/D)
Have in terms of pre- preventing obesity and have certain effect.
Prevention group mouse diet is more stable as can be seen from Figure 2, and treatment group gos and buy Chinese medicine first day after modeling success and drinks
Appetite reduces, but tends towards stability below, and generally food intake dose is fewer than during modeling for treatment group, it is seen that mangiferin with
Orlistat may have inhibitory action to the appetite of mouse.
From figure 3, it can be seen that all groups no notable difference in total triglycerides (TG) level of mice serum；
The normal control group .1 of T-CHOL (TC) content, normal control group .2, model group, the height of prevention in each group serum
Dosage group, prevention low dose group are 2.82mmol/L, 2.69mmol/L, 4.47mmol/L, 3.96mmol/L respectively,
3.74mmol/L.
Prevention group mangiferin low dosage (50mg/kg/D) and prevention group high dose (200mg/kg/D) are compared with model group
Show significant difference in TC levels in mice serum is reduced, show prevention group mangiferin low dosage (50mg/kg/D) and
Prevention group high dose (200mg/kg/D) has significant effect；
Normal group is with prevention group mangiferin low dosage in mice serum middle-high density lipoprotein concentration (HDL-C) in model
Group compares with significant difference, and other all groups do not show significant difference, and Orlistat
(55mg/kg/D), treatment group's mangiferin low dosage (50mg/kg/D), treatment group mangiferin high dose (200mg/kg/D) model
The water of HDL-C in group, prevention group mangiferin low dosage (50mg/kg/D) and prevention group high dose (200mg/kg/D) mice serum
It is flat to increase compared with normal group；
Normal control group .1, normal control group .2, model group, ldl concn in the serum of low dose group is prevented
It is 0.26mmol/L, 0.27mmol/L, 0.62mmol/L and 0.45mmol/L. respectively
Prevention group mangiferin low dosage (50mg/kg/D) relatively shows significant difference with model group, shows prevention group
Mangiferin low dosage (50mg/kg/D) has the effect for being significantly reduced LDL-C in mice serum；
Leptin synthesizes in white adipose tissue, and in obese people, the content of leptin is very high, this causes can generation
Thank to disorder.Fatty acid synthetase is an important enzyme during Adipogenesis, and this patent also has detected compound mangiferin
Activity on fatty acid synthetase.
From fig. 4, it can be seen that in the serum of normal control group .2, model group, prevention high dose combination prevention low dose group
The concentration of leptin is 1.57 × 10 respectively3pg/mL,1.43×104pg/mL,5.36×103Pg/mL and 3.79 × 103pg/mL.
Prevention group mangiferin low dosage low dosage (50mg/kg/D) and prevention group high dose (200mg/kg/D) and treatment group's mangiferin
High dose shows significant effect in mice serum is reduced in terms of leptin.The reduction of leptin influences mouse appetite, and then
Play antiobesity action.
Mangiferin does not have inhibitory action to fatty acid synthetase as can be seen from Figure 4.
Fig. 5 histotomy the results shows give the mouse of mangiferin and the adipocyte of the mouse of Orlistat compares model group
It is more very thin, and each group of hepatic tissue section does not change substantially, this shows that mangiferin is without pair for the liver of mouse
Effect.
Weight-reducing mechanism：It may be by inhibiting the expression of Leptin in mice serum and then influence the appetite and drop of mouse
TC and LDL-C in low serum and play the effect of weight-reducing.
Embodiment 3：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, routinely adds injection
Parenteral solution is made in water, refined filtration, embedding sterilizing.
Embodiment 4：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, is dissolved in sterile note
It penetrates in water, stirring makes molten, is filtered with sterile suction funnel, then sterile refined filtration, is sub-packed in 2 ampoules, after frozen drying
It is sterile to seal to obtain powder-injection.
Embodiment 5：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, with excipient weight ratio
For 9:1 ratio adds in excipient, and pulvis is made.
Embodiment 6：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, by itself and excipient weight
Amount is than being 1:5–1:10 ratio adds in excipient, pelletizing press sheet.
Embodiment 7：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, routinely oral liquid system
Oral liquid is made in method.
Embodiment 8：
Mangiferin, mango glucoside extract, mangiferin analog are first made as described in Example 1, by itself and excipient weight
Amount is than being 3:1 ratio adds in excipient, and capsule or granule or electuary is made.
Embodiment 9：
12.4 grams of mangiferin, mango glucoside extract or mangiferin analog are made as described in Example 1, adds in starch
600 grams, 200 grams of lactose, 5 grams of menthol, lozenge is made, as functional food in 183 grams of sodium carboxymethyl starch.
Claims (8)
1. application of the mangiferin and the like in slimming medicine or food is prepared, it is characterised in that the mango leaf extract
Middle mangiferin and the like total content is 60-90%, and the mangiferin analog is a kind of monomeric compound or arbitrary a variety of
The mixture of compound, the mangiferin analog structural formula general formula are as follows：
Wherein, R1、R7For the change of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl, methylol, ethoxy, carboxyphenyl and various sugar
Close object；R8、R10For the compound of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl and various sugar；R11For hydrogen, hydroxyl, methoxy
Base, ethyoxyl, methylol, ethoxy, carboxymethyl, carboxyethyl.
2. application of the mangiferin and the like in slimming medicine or food is prepared, it is characterised in that the mangiferin is under
Method extraction is stated to obtain：It is dried after 40 kilograms of mango leaf harvestings, breaks into coarse powder, 60% ethanol water, dip time 6h, feed liquid
Than 1:20, then purified with carrying out initial gross separation to mango flavones crude extract on last stage using macroreticular resin, action of going forward side by side
State absorption, elution；After the extract obtained sodium bicarbonate solution dissolving with pH=8 of previous step, certain 75% acetic acid is added in
Mango extract crude product 100g is precipitated to obtain, mangiferin crude product methanol at 40 DEG C is dissolved by heating, is concentrated into after being completely dissolved just
First subcrystalline mangiferin in 4 DEG C of crystallisation by cooling, is repeated above step and crystallized again by the 15% of beginning volume of dissolution, final
To more than 95% mangiferin.
3. application of the mango leaf extract in slimming medicine or food is prepared, it is characterised in that awns in the mango leaf extract
Fruit glycosides and the like total content is 60-90%, and the mango leaf extract is extracted by following methods and obtained：40 kilograms of mango leafs
It is dried after harvesting, breaks into coarse powder, 60% ethanol water, dip time 6h, solid-liquid ratio 1:20, then with using macroreticular resin pair
Mango flavones crude extract on last stage carries out initial gross separation purifying, Mobile state of going forward side by side absorption, elution；It will be extracted obtained by previous step
For object with after the sodium bicarbonate solution dissolving of pH=8, the acetic acid for adding in certain 75% precipitates to obtain mango extract crude product 100g.
4. application according to claim 3, wherein the mango leaf extract is with the change shown in following general structural formula
It is main component to close object flavonoids and flavonoid glycoside compounds,
In formula, R1、R7For the change of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl, methylol, ethoxy, carboxyphenyl and various sugar
Close object；R8、R10For the compound of the formation such as hydrogen, hydroxyl, methoxyl group, ethyoxyl and various sugar；R11For hydrogen, hydroxyl, methoxy
Base, ethyoxyl, methylol, ethoxy, carboxymethyl, carboxyethyl.
5. mangiferin and the like or mango glucoside extract are preparing the drug for the treatment of obesity caused by high fat diet
In application.
6. according to the application described in claim 1 or 2 or 3, it is characterised in that mangiferin and the like action pathway is inhibition
The expression of Leptin in serum, and then the appetite of organism is influenced, TC and LDL-C in serum is reduced, so as to play antiobesity action.
7. pharmaceutical composition, the mangiferin containing therapeutically effective amount and the like or mango glucoside extract and pharmaceutical acceptable carrier.
8. pharmaceutical composition according to claim 7, wherein described mangiferin and the like is because of dissolving and pharmacodynamics poison
Demand of science, further difference or any or several compounds mixing add in sulfonyls, phosphate radical, sodium salt, sylvite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711363842.3A CN108096238A (en) | 2017-12-18 | 2017-12-18 | Application of the mangiferin and the like in slimming medicine or food is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711363842.3A CN108096238A (en) | 2017-12-18 | 2017-12-18 | Application of the mangiferin and the like in slimming medicine or food is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108096238A true CN108096238A (en) | 2018-06-01 |
Family
ID=62210834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711363842.3A Pending CN108096238A (en) | 2017-12-18 | 2017-12-18 | Application of the mangiferin and the like in slimming medicine or food is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108096238A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292546A (en) * | 2021-05-24 | 2021-08-24 | 深圳大学 | Mangiferin derivative and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920696A (en) * | 2012-09-27 | 2013-02-13 | 戴好富 | Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and to preparation of medicament or food for preventing and treating obesity |
-
2017
- 2017-12-18 CN CN201711363842.3A patent/CN108096238A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920696A (en) * | 2012-09-27 | 2013-02-13 | 戴好富 | Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and to preparation of medicament or food for preventing and treating obesity |
Non-Patent Citations (3)
| Title |
|---|
| 李学坚等: "D101大孔树脂吸附芒果苷的影响因素", 《中国实验方剂学杂志》 * |
| 李学坚等: "采用水基溶剂提取芒果苷的工艺研究", 《中成药》 * |
| 邓妍芳等: "大孔吸附树脂AB-8 对芒果苷吸附及扩散动力学的影响", 《中国药房》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292546A (en) * | 2021-05-24 | 2021-08-24 | 深圳大学 | Mangiferin derivative and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI454269B (en) | Compounds isolated from xanthoceras sorbifolia, methods for preparing same and uses thereof | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| KR101158856B1 (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient | |
| TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
| JP2012207009A (en) | Method for producing mulberry twig pulverized powder | |
| CN102552372A (en) | Novel purpose of eucommia chemical components as blood vessel protective agent | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| CN114796245A (en) | New application of dendrobe oligosaccharide | |
| CN101904907B (en) | Buckwheat extract abundant in inositol and general flavone and preparation method thereof | |
| CN108096238A (en) | Application of the mangiferin and the like in slimming medicine or food is prepared | |
| KR20150083622A (en) | Anti-obesity composition using acanthopanax sessiliflorus and mulberry | |
| CN110327399A (en) | Beautyberry extract is preparing the application in fat-reducing medicament | |
| EP3616705A2 (en) | Composition for improving prevention and treatment of fatty liver containingamomum vilosum | |
| CN105640971A (en) | Application of total saponins in unripe siraitia grosvenorii fruit extract in preparation of assistant hypoglycemic drug | |
| CN106822095B (en) | Medicine for preventing and treating fatty liver and obesity and application thereof in pharmacy | |
| CN101278970A (en) | Method for preparing Elsholtzia bodinieri flavonoid and applications | |
| CN111249271A (en) | Medicament for treating diabetes and preparation method and application thereof | |
| CN102281882A (en) | Postprandial hyperglycemia-improving agent | |
| EP1416927A1 (en) | Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect | |
| CN110123827A (en) | A kind of pharmaceutical composition and its preparation method and application treated by metabolic disorder associated diseases | |
| KR20020065120A (en) | Active fraction having inhibitory effects on fatty acid synthase isolated from piper longum | |
| KR100443264B1 (en) | Active fractions having inhibitory effect on protein tyrosine phosphatase 1B isolated from Psidium guajava | |
| JP5864003B1 (en) | Novel Rakan fruit extract composition having lipid accumulation inhibitory effect | |
| CN110624006A (en) | A health wine containing effective components of fructus Quzhazhii | |
| CN114681563B (en) | Pharmaceutical composition containing erigeron breviscapus, ginseng, ophiopogon root and schisandra chinensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180601 |